Scholarlink

Background <p>Lung cancer is a leading cause of cancer mortality, largely due to late-stage diagnosis. Biomarker detection is critical for early screening, molecular subtyping, and personalized therapy. This review summarizes the categories of lung cancer biomarkers, evaluates recent advances in detection technologies, and assesses their clinical potential and associated challenges.</p> Methods <p>Biomarkers were systematically categorized into three categories: molecular (DNA, RNA, proteins), epigenetic (e.g., DNA methylation), and liquid biopsy-based (e.g., ctDNA, CTCs, exosomes). Detection platforms were analyzed, including gene-based techniques (PCR, NGS, FISH), protein-based methods (IHC, ELISA, MS), liquid biopsy workflows, and emerging biosensors. The principles, applications, and limitations of each technology were critically examined. </p> Results <p>Biomarkers and detection technologies serve complementary roles. Tissue-based assays (e.g., IHC, PCR) remain foundational for molecular profiling. Liquid biopsies (e.g., NGS, dPCR) enable non-invasive monitoring of therapy and resistance analysis. Novel biosensors provide ultra-high sensitivity (fg/mL to aM level) for early detection. Challenges include low abundance of early-stage biomarkers, lack of standardization, tumor heterogeneity, and clinical translation hurdles.</p> Conclusions <p>The field is moving towards multi-omics integration, ultra-sensitive detection, and standardization. Combining multiple biomarkers, utilizing complementary technologies, and facilitating the clinical adoption of innovative platforms are essential for enhancing early diagnosis and enabling precision oncology in lung cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The progress of biomarkers detection to lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • Haifeng Qi,
  • Feng Li,
  • Lang Peng,
  • Jinxing Lin,
  • Zhihua Jiang

摘要

Background

Lung cancer is a leading cause of cancer mortality, largely due to late-stage diagnosis. Biomarker detection is critical for early screening, molecular subtyping, and personalized therapy. This review summarizes the categories of lung cancer biomarkers, evaluates recent advances in detection technologies, and assesses their clinical potential and associated challenges.

Methods

Biomarkers were systematically categorized into three categories: molecular (DNA, RNA, proteins), epigenetic (e.g., DNA methylation), and liquid biopsy-based (e.g., ctDNA, CTCs, exosomes). Detection platforms were analyzed, including gene-based techniques (PCR, NGS, FISH), protein-based methods (IHC, ELISA, MS), liquid biopsy workflows, and emerging biosensors. The principles, applications, and limitations of each technology were critically examined.

Results

Biomarkers and detection technologies serve complementary roles. Tissue-based assays (e.g., IHC, PCR) remain foundational for molecular profiling. Liquid biopsies (e.g., NGS, dPCR) enable non-invasive monitoring of therapy and resistance analysis. Novel biosensors provide ultra-high sensitivity (fg/mL to aM level) for early detection. Challenges include low abundance of early-stage biomarkers, lack of standardization, tumor heterogeneity, and clinical translation hurdles.

Conclusions

The field is moving towards multi-omics integration, ultra-sensitive detection, and standardization. Combining multiple biomarkers, utilizing complementary technologies, and facilitating the clinical adoption of innovative platforms are essential for enhancing early diagnosis and enabling precision oncology in lung cancer.